Solid Tumors Clinical Trial
Official title:
A Phase I Trial of Nelfinavir (Viracept) in Adults With Solid Tumors
Background:
- The PI3K/Akt/mTOR pathway is an important target in cancer because it promotes
chemotherapeutic resistance and confers a poor prognosis for many types of cancers.
- Several inhibitors of the pathway are being developed as cancer therapeutics. However,
the process of de novo drug development takes years, and is often curtailed due to
diminished activity and/or unforeseen toxicities in clinical trials.
- One approach to expedite the development of new cancer therapies is to test drugs that
are already approved for other indications.
- Our group has shown that nelfinavir, an orally available FDA-approved HIV-1 protease
inhibitor used to treat HIV/AIDS, can inhibit endogenous Akt and growth factor receptor
induced Akt activity in cancer cells.
- Importantly, nelfinavir demonstrates dose-dependent cytotoxicity in every cell line in
the NCI 60 cell line panel at plasma concentrations attainable in human plasma, is
profoundly effective in cancer cell lines that have been selected to become resistant to
standard therapies, and inhibits tumor growth in-vivo.
Objectives:
- Because an MTD with nelfinavir has not been observed in prior phase I studies with HIV
patients, the objectives of the Phase I design will be:
- To establish the MTD and dose limiting toxicity for this drug in patients with solid
Tumors.
- To correlate nelfinavir pharmacokinetics with baseline activity of CYP3A4 as assessed by
measuring midazolam clearance.
- To preliminarily explore the biological and clinical effects through a series of
correlative studies involving analysis of blood and tissue across patients throughout
the study.
Eligibility:
-Adults with solid tumors who are refractory to, or have relapsed after receiving, standard
front-line chemotherapies are eligible.
Design:
- Patients will receive nelfinavir beginning at the FDA-approved dose for HIV patients
(1250 mg po bid).
- Dose escalations will occur for 6 dose levels i.e. cohorts, or until the MTD is reached.
- Up to 45 patients are expected to be enrolled.
- Staging CT scans will be performed every two cycles.
Background:
-The PI3K/Akt/mTOR pathway is an important target in cancer because it promotes
chemotherapeutic resistance and confers a poor prognosis for many types of cancers.
- Several inhibitors of the pathway are being developed as cancer therapeutics. However,
the process of de novo drug development takes years, and is often curtailed due to
diminished activity and/or unforeseen toxicities in clinical trials.
- One approach to expedite the development of new cancer therapies is to test drugs that
are already approved for other indications.
- Our group has shown that nelfinavir, an orally available FDA-approved HIV-1 protease
inhibitor used to treat HIV/AIDS, can inhibit endogenous Akt and growth factor receptor
induced Akt activity in cancer cells.
-Importantly, nelfinavir demonstrates dose-dependent cytotoxicity in every cell line in the
NCI 60 cell line panel at plasma concentrations attainable in human plasma, is profoundly
effective in cancer cell lines that have been selected to become resistant to standard
therapies, and inhibits tumor growth in-vivo.
Objectives:
-Because an MTD with nelfinavir has not been observed in prior phase I studies with HIV
patients, the objectives of the Phase I design will be:
-To establish the MTD and dose limiting toxicity for this drug in patients with solid
Tumors.
-To correlate nelfinavir pharmacokinetics with baseline activity of CYP3A4 as
assessed by measuring midazolam clearance.
-To preliminarily explore the biological and clinical effects through a series of
correlative studies involving analysis of blood and tissue across patients throughout
the study.
Eligibility:
-Adults with solid tumors who are refractory to, or have relapsed after receiving, standard
front-line chemotherapies are eligible.
Design:
- Patients will receive nelfinavir beginning at the FDA-approved dose for HIV patients
(1250 mg po bid).
- Dose escalations will occur for 6 dose levels i.e. cohorts, or until the MTD is reached.
- Up to 45 patients are expected to be enrolled.
- Staging CT scans will be performed every two cycles.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |